Supp table 1: Clinical information about Lower Grade Glioma and Glioblastoma Multiforme datasets.

| **Lower Grade Glioma (n=516)** | **Glioblastoma multiforme (n=395)** |
| --- | --- |
| Age at initial pathologic diagnosis (n=516)  [14 > 87] | Chemo therapy (n=395)  Nd 0.3%  No 17.2%  Null 12.7%  Yes 69.9% |
| Days to death (n=516)  [7 > 4445] | Gender (n=395)  Female 35.9%  Male 60%  Nd 0.3%  Null 3.8% |
| Ethnicity (n=516)  Hispanic or latino 6.2%  Nd 2.7%  Not evaluated 0.2%  Not hispanic or latino 87%  Unknown 3.9% | Histological type (n=395)  Nd 0.3%  Null 3.8%  Treated primary GBM 3.8%  Untreated primary (de novo) GBM 92.2% |
| Gender (n=516)  Female 44.6%  Male 55.2%  Nd 0.2% | Immunotherapy (n=395)  Nd 0.3%  No 89.9%  Null 6.8%  Yes 3% |
| Histologic diagnosis (n=516)  Astrocytoma 37.6%  Oligoastrocytoma 25.2%  Oligodendroglioma 37%  Nd 0.2% | Radiation therapy (n=395)  Nd 0.3%  No 11.6%  Null 6.1%  Yes 82% |
| Idh1 mutation found (n=516)  Nd 75%  No 6.6%  Unknown 0.8%  Yes 17.6% | Targeted molecular therapy (n=395)  Nd 0.3%  No 77.7%  Null 6.8%  Yes 15.2% |
| Tumor grade (n=516)  Discrepancy\* 0.2%  Grade 2 48.3%  Grade 3 51.4%  Nd 0.2% | Vital status (n=395)  Alive 14.1%  Dead 81.5%  Null 4.1% |
| Vital status (n=516)  Alive 82%  Dead 17.8%  Nd 0.2% |  |
|  |  |

\*Probably patients with Oligoastrocytoma